

PATENT ASSIGNMENT

Electronic Version v1.1  
Stylesheet Version v1.1

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	CHANGE OF NAME
CONVEYING PARTY DATA	
Name	Execution Date
Genesee BioMedical, Inc.	04/19/2011
RECEIVING PARTY DATA	
Name:	Medtronic GBI, Inc.
Street Address:	710 Medtronic Parkway
City:	Minneapolis
State/Country:	MINNESOTA
Postal Code:	55432-5604
PROPERTY NUMBERS Total: 10	
Property Type	Number
Patent Number:	6187040
Patent Number:	5201880
Patent Number:	5306296
Patent Number:	5674279
Patent Number:	5522884
Patent Number:	7691143
Application Number:	12721019
Application Number:	11627838
Application Number:	12643073
PCT Number:	US0969040
CORRESPONDENCE DATA	
Fax Number:	(707)543-5420
Phone:	707 525 0111
Email:	rs.vasciplegal@medtronic.com
Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent via US Mail.	

CH \$400.00 6187040

501693595

PATENT  
REEL: 027073 FRAME: 0492

Correspondent Name: Kim Grigg  
Address Line 1: 3576 Unocal Place  
Address Line 2: IP Legal Department  
Address Line 4: Santa Rosa, CALIFORNIA 95403

ATTORNEY DOCKET NUMBER: G666 GENESEE

NAME OF SUBMITTER: William L. Haynes, Patent Counsel

**Total Attachments: 7**

source=G666NameChangeMDTGBI#page1.tif  
source=G666NameChangeMDTGBI#page2.tif  
source=G666NameChangeMDTGBI#page3.tif  
source=G666NameChangeMDTGBI#page4.tif  
source=G666NameChangeMDTGBI#page5.tif  
source=G666NameChangeMDTGBI#page6.tif  
source=G666NameChangeMDTGBI#page7.tif

## CHANGE OF NAME CONFIRMATION

I, Keyna P. Skeffington, Vice President, Deputy General Counsel and Assistant Secretary of Medtronic, Inc., do hereby declare that:

1. An Agreement and Plan of Merger (the "**Agreement**") was made and entered into as of February 14, 2011 by and among others, **MEDTRONIC, INC.**, a Minnesota corporation, located at 710 Medtronic Parkway, Minneapolis, Minnesota 55432-5604, USA, and **Genesee BioMedical, Inc.**, a Colorado corporation, with a place of business at 1308 S. Jason Street, Denver, Colorado 80223, USA,
2. The above-identified transaction closed on or about April 19, 2011;
3. A corporation name change from Genesee BioMedical, Inc. to Medtronic GBI, Inc., was filed on or about April 19, 2011 (Exhibit A); and
4. Pursuant to the Agreement followed by corporate name change, the attached list of patents, and patent applications (Schedule B) became owned by **Medtronic GBI, Inc.**, a Colorado corporation. The principal office address of the corporation is 710 Medtronic Parkway, Minneapolis, MN 55432-5604.

Please record this Name Change for each of the attached patents, and patent applications.

Date: October 17, 2011



Keyna P. Skeffington  
Vice President, Deputy General Counsel  
and Assistant Secretary  
Medtronic, Inc.

EXHIBIT A



Colorado Secretary of State  
Date and Time: 04/19/2011 10:42 AM  
ID Number: 19941108590  
Document number: 20111234620  
Amount Paid: \$25.00

Document must be filed electronically.  
Paper documents will not be accepted.

Document processing fee  
Fees & forms/cover sheets  
are subject to change.

\$25.00

To access other information or print  
copies of filed documents,  
visit [www.sos.state.co.us](http://www.sos.state.co.us) and  
select Business.

ABOVE SPACE FOR OFFICE USE ONLY

**Amended and Restated Articles of Incorporation**

filed pursuant to §7-90-301, et seq. and §7-110-107 and §7-90-304.5 of the Colorado Revised Statutes (C.R.S.)

ID number: 19941108590

1. Entity name: GENESEE BIOMEDICAL, INC.

*(If changing the name of the corporation, indicate name BEFORE the name change)*

2. New Entity name:  
(if applicable)

Medtronic GBI, Inc.

3. Use of Restricted Words *(if any of these  
terms are contained in an entity name, true  
name of an entity, trade name or trademark  
stated in this document, mark the applicable  
box):*

- ☐ "bank" or "trust" or any derivative thereof  
☐ "credit union" ☐ "savings and loan"  
☐ "insurance", "casualty", "mutual", or "surety"

4. If the corporation's period of duration  
as amended is less than perpetual, state  
the date on which the period of duration  
expires:

*(mm/dd/yyyy)*

OR

If the corporation's period of duration as amended is perpetual, mark this box: ☒

5. The amended and restated constituent filed document is attached.

6. If the amendment provides for an exchange, reclassification or cancellation of issued shares, the attachment  
states the provisions for implementing the amendment.

7. (Optional) Delayed effective date:

*(mm/dd/yyyy)*

Notice:

Causing this document to be delivered to the secretary of state for filing shall constitute the affirmation or  
acknowledgment of each individual causing such delivery, under penalties of perjury, that the document is the  
individual's act and deed, or that the individual in good faith believes the document is the act and deed of the  
person on whose behalf the individual is causing the document to be delivered for filing, taken in conformity  
with the requirements of part 3 of article 90 of title 7, C.R.S., the constituent documents, and the organic  
statutes, and that the individual in good faith believes the facts stated in the document are true and the  
document complies with the requirements of that Part, the constituent documents, and the organic statutes.

This perjury notice applies to each individual who causes this document to be delivered to the secretary of  
state, whether or not such individual is named in the document as one who has caused it to be delivered.

8. Name(s) and address(es) of the individual(s) causing the document to be delivered for filing:

Taylor	Julie	A	
(Last)	(First)	(Middle)	(Suffix)
200 South 6th St			
(Street name and number or Post Office Box information)			
Suite 4000			
Minneapolis	MN	55402	
(City)	(State)	(Postal/Zip Code)	
United States			
(Country - if not US)			

(The document need not state the true name and address of more than one individual. However, if you wish to state the name and address of any additional individuals causing the document to be delivered for filing, mark this box ☐ and include an attachment stating the name and address of such individuals.)

**Disclaimer:**

This form, and any related instructions, are not intended to provide legal, business or tax advice, and are offered as a public service without representation or warranty. While this form is believed to satisfy minimum legal requirements as of its revision date, compliance with applicable law, as the same may be amended from time to time, remains the responsibility of the user of this form. Questions should be addressed to the user's attorney.

**AMENDED AND RESTATED ARTICLES OF INCORPORATION  
OF  
GENESEE BIOMEDICAL, INC.**

Filed pursuant to §7-90-301, et seq. and §7-110-107 and §7-90-304.5  
of the Colorado Revised Statutes (C.R.S.)

1. Name. The name of the corporation is: Medtronic GBI, Inc.

2. Principal Office Address. The principal office address of the corporation is:

Street address: 710 Medtronic Parkway NE  
Minneapolis, MN 55432-5604

3. Registered Agent and Registered Office Address. The registered agent name and registered agent address of the corporation's registered agent are:

Agent: The Corporation Company

Street address: 1675 Broadway  
Suite 1200  
Denver, CO 80202

4. Authorized Shares. The corporation is authorized to issue 2,500 common shares that shall have unlimited voting rights and are entitled to receive the net assets of the corporation upon dissolution.

5. Par Value. The shares shall have \$.01 par value. Holders of Common Stock shall be entitled to one vote for each share of Common Stock held of record.

6. Issuance of Shares to Holders of Another Class or Series. The Board of Directors is authorized to issue shares of the corporation of one class or series to holders of that class or series or to holders of another class or series to effectuate share dividends or splits.

7. No Cumulative Voting Rights. No shareholder shall be entitled to cumulate votes for the election of directors and there shall be no cumulative voting for any purpose whatsoever.

8. Voting Agreements. A written agreement among shareholders or subscribers for shares to be issued, relating to the voting of their shares, is valid and specifically enforceable by and against the parties to the agreement under Section 7-107-302 of the Colorado Revised Statutes.

9. Written Action by the Shareholders. Actions required or permitted to be taken by the shareholders may be taken without a meeting if shareholders holding shares having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all of the shares entitled to vote thereon were present and voted consent to such action in writing.

10. Indemnification. The corporation shall indemnify, to the maximum extent permitted by applicable law in effect from time to time, any person, and the estate and personal representative of any such person, against all liability and expense (including attorneys' fees) incurred by reason of the fact that such person is or was a director, officer, agent, fiduciary, or employee of the corporation or, while serving as a director, officer, agent, fiduciary, or employee of the corporation, such person is or was serving at the request of the corporation as a director, officer, partner, trustee, employee, fiduciary or agent of, or in any similar managerial or fiduciary position of, another domestic or foreign corporation or other individual or entity or of an employee benefit plan. The corporation shall also indemnify any person who is serving or has served the corporation as a director, officer, agent, fiduciary, or employee, and that person's estate or personal representative, to the extent and in the manner provided in any bylaw, resolution of the shareholders or directors, contract, or otherwise, so long as such provision is legally permissible. The corporation shall further have the authority, to the maximum extent permitted by law, to purchase and maintain insurance providing for such indemnification.

11. Limitation of Director Liability. No director of the corporation shall be personally liable to the corporation or its shareholders for monetary damages for breach of fiduciary duty by such director as a director; provided, however, that this Article shall not eliminate or limit the liability of a director to the corporation or its shareholders for monetary damages for (i) any breach of the director's duty of loyalty to the corporation or its shareholders, (ii) acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) acts specified in Section 7-108-403 of the Colorado Revised Statutes, or (iv) any transaction from which the director derived an improper personal benefit. Nothing contained herein will be construed to eliminate or diminish the defenses ordinarily available to a director or to deprive any director of any right he or she may have for contribution from any other director or other person. If the Colorado Business Corporation Act hereafter is amended to eliminate or limit further the liability of a director, then, in addition to the elimination and limitation of liability provided by the preceding sentence, the liability of each director shall be eliminated or limited to the fullest extent permitted by the Colorado Business Corporation Act as so amended. Any repeal or modification of this Article shall not adversely affect any right or protection of a director of the corporation under this Article, as in effect immediately prior to such repeal or modification, with respect to any liability that would have accrued, but for this Article, prior repeal or modification.

IMATTER NO	SERIAL NO	PATENTN O	PUBLNO
0025.34A	09/303,864	6,187,040	
25.55	07/826,405	5,201,880	
0025.55/PC T	PCT/US93/ 00767		
25.56	07/933,339	5,306,296	
0025.56/DI V*	08/188,624		
25.57	08/437,448	5,674,279	
25.58	08/019,515	5,522,884	
25.59	EP624080A 1		
25.66	11/534,188	7,691,143	US-2007-0067028-A1
0025.66/C	12/721,019		US-2010-0168846-A1
0025.66/PC T	PCT/US200 6/36851		WO 2007/03588 2
0025.66/PR	60/719,483		
25.68	11/627,838		US-2007-0179603-A1
0025.68-PR	60/763,005		
0025.69-PR	60/824,894		
25.74	12/643,073		US-2010-0168845-A1
0025.74/PC T	PCT/US09/ 69040		WO 2010/07812 1
0025.74-PR	61/142,073		
0025.79-PR	61/301,158		
0025.79-PR2	61/301,532		



<b>TITLE</b>	<b>STATUS</b>	<b>FILE</b>	<b>ISSUE</b>
Mitral and Tricuspid Annuloplasty Rings	ISSUED	5/3/1999	2/13/2001
Mitral and Tricuspid Annuloplasty Rings	ISSUED	1/27/1992	4/13/1993
Annuloplasty and Suture Rings	NAT PHASE	1/26/1993	
Annuloplasty and Suture Rings	ISSUED	8/21/1992	4/26/1994
Annuloplasty and Suture Rings	ABANDONED	1/28/1994	
Annuloplasty and Suture Rings	ISSUED	6/29/1995	10/7/1997
Holder for Adjustable Mitral and Tricuspid Annuloplasty	ABANDONED	2/19/1993	6/4/1996
Annuloplasty and Suture Rings	ABANDONED	1/26/1993	
ANNULOPLASTY RING HOLDER	ISSUED	9/21/2006	4/6/2010
ANNULOPLASTY RING HOLDER	PUBLISHED	3/10/2010	
ANNULOPLASTY RING HOLDER	ABANDONED	9/21/2006	
ANNULOPLASTY RING HOLDER	EXPIRED	9/21/2005	
Heatset Annuloplasty Suture Guide	PUBLISHED	1/26/2007	
Heatset Annuloplasty Suture Guide	EXPIRED	1/27/2006	
ANNULOPLASTY RING	ABANDONED	9/7/2006	
Semi-Rigid Annuloplasty Ring and Band	PUBLISHED	12/21/2009	
Semi-Rigid Annuloplasty Ring and Band	PUBLISHED	12/21/2009	
Semi-Rigid Annuloplasty Ring and Band	EXPIRED	12/31/2008	
Semi-Flexible Annuloplasty Ring	PENDING	2/3/2010	
Semi-Flexible Annuloplasty Ring	PENDING	2/4/2010	